Cetirizine Hydrochloride
NDC 47335-343
Product Information
Cetirizine Hydrochloride is a ANDA-approved product labeled by Sun Pharmaceutical Industries, Inc.. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a purple product. This product entry covers the primary NDC 47335-343 and 4 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
343
Code Structure Chart
Product Details
What is NDC 47335-343?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CETIRIZINE HYDROCHLORIDE (UNII: 64O047KTOA)
- CETIRIZINE (UNII: YO7261ME24) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- ACESULFAME POTASSIUM (UNII: 23OV73Q5G9)
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- SUCROSE (UNII: C151H8M554)
- CROSPOVIDONE (UNII: 68401960MK)
- FD&C BLUE NO. 2 (UNII: L06K8R7DQK)
- FD&C RED NO. 40 (UNII: WZB9127XOA)
- GUAR GUM (UNII: E89I1637KE)
- MAGNESIUM OXIDE (UNII: 3A3U0GI71G)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- MANNITOL (UNII: 3OWL53L36A)
- CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
- STARCH, CORN (UNII: O8232NY3SJ)
- TALC (UNII: 7SEV7J4R1U)
* Please review the full disclaimer at the bottom of this page.
Patient Education
Cetirizine Injection
Cetirizine injection is used to treat acute urticaria in adults and children 6 months of age or older. Cetirizine is in a class of medications called antihistamines. It works by blocking the action of histamine, a substance in the body that causes allergic symptoms.
[Learn More]
* Please review the full disclaimer at the bottom of this page.